Rodman & Renshaw Reiterates Buy on Emergent BioSolutions, Maintains $16 Price Target
Emergent BioSolutions Analyst Ratings
Emergent Biosolutions Price Target Announced at $16.00/Share by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On Emergent BioSolutions With Buy Rating, Announces Price Target of $16
Emergent BioSolutions Analyst Ratings
Rodman & Renshaw Upgrades Emergent BioSolutions(EBS.US) to Buy Rating, Cuts Target Price to $16
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Emergent BioSolutions Analyst Ratings
Emergent BioSolutions Analyst Ratings
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Emergent BioSolutions Analyst Ratings
Emergent BioSolutions Analyst Ratings
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $8 Price Target
Emergent BioSolutions Analyst Ratings
Benchmark: Reiterates the Emergent BioSolutions (EBS.US) rating and adjusted from buy to buy, with a target price of $5.00.
Emergent BioSolutions Analyst Ratings
Analysts' Top Healthcare Picks: Emergent Biosolutions (EBS), Vera Therapeutics (VERA)